An interim analysis of a cohort in the CheckMate-205 study showed that nivolumab had an acceptable safety profile and demonstrated efficacy among patients with relapsed and refractory classical Hodgkin lymphoma after post-auto-HCT brentuximab vedotin.
The gene expression-based prognostic model, RHL30, has the potential to provide insights for the selection of treatment strategies catered to the individual patient.
Long-term follow-up data from randomized trials on Hodgkin lymphoma support current risk-adapted therapeutic approaches for early-stage disease.
Pembrolizumab treatment resulted in high ORRs among patients with relapsed/refractory classic Hodgkin lymphoma regardless of previous therapy.
Survivors with a family history of colorectal, breast, and lung cancer were at a significantly higher risk of similar second cancers.
PD-1 blockade with nivolumab was active in patients with Hodgkin lymphoma who received allogeneic hematopoietic cell transplantation.
Adjusting treatment dose after 2 courses of first-line therapy based on a positive PET scan does not improve progression-free survival.
Treatment with anthracyclines increases the risk for developing heart failure by 3-fold independently of radiation dose among survivors of Hodgkin lymphoma.
A diagnosis of Waldenstrom’s Macroglobulinemia can leave you and your loved ones feeling uncertain, anxious and overwhelmed.
BeGEV appears to provide clinical benefit for patients with relapsed or refractory Hodgkin lymphoma, and ought to be developed further.
